艾司西酞普兰治疗抑郁症伴焦虑的疗效分析

目的评价国产艾司西酞普兰片治疗抑郁症伴焦虑的疗效及安全性。方法本研究为6周的多中心开放性研究,共入组符合CCMD-3诊断标准的抑郁症(同时HAMD≥17分、HAMA≥14分)患者173例,服用国产艾司西酞普兰片的剂量为10mg-20mg/d,分别在治疗前及第1、2、4、6周末以汉密尔顿抑郁量表17项(HAMD)、汉密尔顿焦虑量表(HAMA)和临床总体印象量表CGI(包括病情严重程度评分CGI-SI、疗效评分CGI-GI)评定疗效,以不良事件记录表、体格检查、实验室检查评估用药安全性。结果共169例患者完成研究,经6周治疗后显示,HAMD、HAMA、CGI-SI评分呈现一致的减分趋势,各时点HAMD-17、HAMA、CGI-SI的总分与治疗前比较,差异均有显著性(P<0.05),总体有效率为81.1%、痊愈率是63.9%。不良反应发生率为10.06%,一般可以耐受。结论国产艾司西酞普兰片治疗抗抑郁及焦虑作用确切,可用于治疗抑郁症伴焦虑障碍。

Efficacy of Escitalopram in the treatment of major depressive disorders with anxiety symptoms

Objective The objective of this study was to assess the efficacy and tolerability of escitalopram 10 to 20 mg/d for treating the patients of major depressive disorders with anxiety.Methods This is an open-label,multicentre,flexible-dose(10~20 mg/d) and 6 weeks treatment clinical trial.Outpatients and inpatients were enrolled to accept escitalopram treatment for 6 weeks if they met with the CCMD-3 criteria of depressive episode and had a baseline Hamilton Rating Scale for Depression(HAMD) score of ≥17 and a Hamilton Rating Scale for Anxiety(HAMA) score of≥14.The efficacy was assessed with HAMD、HAMA and CGI at the end of baseline and 1,2,4,6 weeks after treatment,while safety was estimated with adverse event rating scale,laboratory and physical examination.Results The HAMD scores,HAMA scores and CGI-SI scores had significant reduction during 6 weeks escitalopram treatment.The response rate and remission rate were 81.1% and 63.9% respectively.The adverse drug reactions such as nausea and other gastrointestinal discomfort were tolerated.Conclusion Escitalopram has positive effectiveness in major depressive with anxiety disorders.